Contract agreement

Viking Therapeutics Signs $150 Million Manufacturing Deal with CordenPharma for Obesity Drug VK2735

1 month ago talkbio0Tagged alpha 1-antitrypsin, Capacity, Contract agreement, CordenPharma, Fill/finish, GLP-1/GIP Dual Agonist, Obesity, oral formulations, production, subcutaneous, Viking, VK2735

Viking Therapeutics, CordenPharma, VK2735, Obesity drug, GLP-1/GIP dual agonist, Contract manufacturing, API production, Fill/finish capacity, Subcutaneous and oral formulations

Johnson & Johnson Sues Samsung Bioepis Over Alleged Stelara Biosimilar Contract Breach

2 months ago talkbio0Tagged Bioepis, Biosimilars, Contract agreement, Johnson and Johnson, Pyzchiva, Samsung, Stelara, ustekinumab

Johnson & Johnson, Samsung Bioepis, Stelara, biosimilar, lawsuit, contract breach, ustekinumab, Pyzchiva

Samsung Biologics Achieves Record Revenue and Secures Largest Contract to Date

3 months ago talkbio0Tagged Biological Factors, Biosimilars, CDMO, Contract agreement, Drug Industry, Largest, Revenue, Samsung

Samsung Biologics, Record Revenue, Largest Contract, Biosimilars, CDMO, Pharmaceutical Industry

Samsung Biologics Embarks on New Phase of Growth with Bio Campus II and ADC Services

3 months ago talkbio0Tagged Antibody-Drug Conjugates, Bio Campus II, Biological Factors, Capacity, CDMO, Contract agreement, development aspects, digital transformation, expansion, Manufacturing Organization, Plants, Samsung, Services

Samsung Biologics, Bio Campus II, Plant 5, antibody-drug conjugate (ADC) services, capacity expansion, digital transformation, contract development and manufacturing organization (CDMO)

Supreme Court Declines to Review PhRMA’s Challenge to Arkansas’ 340B Contract Pharmacy Law

5 months ago talkbio0Tagged 1103, Arkansas, Contract agreement, court, drug price, federal, Pharmacy facility, PhRMA, Programs - Publication Format, Supreme

340B Program, Arkansas Act 1103, PhRMA, Supreme Court, Contract Pharmacies, Drug Pricing, Federal Preemption

Catalent Falls Short of Q1 Revenue Projections Amid Growing Opposition to Novo Holdings’ $16.5 Billion Acquisition

6 months ago talkbio0Tagged Acquisition, Catalent, Contract agreement, Drug Industry, Holdings

Catalent, Q1 Revenue, Novo Holdings, Acquisition, Pharmaceutical Industry, Contract Manufacturing

WuXi AppTec Faces Uncertainty Amid BIOSECURE Act, Yet Continues to Secure New Projects

6 months ago talkbio0Tagged AppTec, Biopharma, BIOSECURE, CDMOs, Contract agreement, Industry, Legislation, manufacturing organizations, National Security Concerns, Outsourcing, United States, WuXi

BIOSECURE Act, WuXi AppTec, Biotechnology Industry, U.S. Legislation, Contract Development and Manufacturing Organizations (CDMOs), Biopharma Outsourcing, National Security Concerns

Fierce Pharma AsiaAstellas’ first-in-class FDA nod; Otsuka’s IgAN win; Samsung Bio’s $1.2B contract

6 months ago talkbio0Tagged Contract agreement, first, IGA Glomerulonephritis, Samsung, Sibeprenlimab, United States Food and Drug Administration

United States Food and Drug Administration, IGA Glomerulonephritis, Sibeprenlimab, Contract agreement, Samsung, first

Samsung Biologics Secures $1.2 Billion Production Contract, Boosting 2024 Deal Value to Over $3.3 Billion

6 months ago talkbio0Tagged Biological Factors, CDMO, Contract agreement, Deal Value, Manufacturing, production, Samsung

Samsung Biologics, CDMO, Contract Manufacturing, Biopharmaceuticals, Production Contract, 2024 Deal Value

BIOSECURE Act: Navigating Industry Implications and Future Directions

7 months ago talkbio0Tagged BIOSECURE, Biotechnology, capabilities, CDMOs, Chinese Language, Contract agreement, development aspects, Industry, Manufacture, manufacturing organizations, pharmaceutical imports, Pharmaceutical supply chain resilience, Supply chain disruptions, United States

BIOSECURE Act, Biotechnology industry, Supply chain disruptions, Chinese pharmaceutical imports, U.S. manufacturing capabilities, Contract development and manufacturing organizations (CDMOs), Pharmaceutical supply chain resilience